Maksillofasial Cerrahinde Botulinum TOKSİN-A Uygulamaları Botulinum Toxin-A Applications in Maxillofacial Surgery

Yıl 2009, Cilt: 3 Sayı: 1, 300 - 305, 01.04.2009

Firdevs Veziroğlu Şenel Kağan Deniz Burak Bayram

Öz

Botulinum toxin-A is one of the 8 subtypes of a strong biological toxin synthesized by Clostridium botulunim which is a gram positive, anaerobic, spore forming organism. Purified botulinum toksin is the first bacterial toxin used as a drug. After the application paresis occurs 2 to 5 days for a time period of 3 - 6 months. Chronic pain, idiopathic trigeminal neuralgias, TMJ disorders, , chronic essential headaches and migraine use are major conditions for botulinum toksin use in the head and neck region.The aim of this article is to give information about botulinum toxin, its application in maxillofacial surgery. Mechanism of action and application dosage were also described. Selected articles were based on review of scientific publications in Medline, Science Direct and Pubmed

Anahtar Kelimeler

Botulinum toxin type A, indications of botulinum toxin

Maksillofasial Cerrahinde Botulinum TOKSİN-A Uygulamaları

Öz

Botulinum toksin-A gram pozitif, anaerob, spor üreten bir organizma olan Clostridium Botulinum tarafından sentezlenen, güçlü biyolojik bir toksinin 8 alt tipinden biridir. Saflaştırılmış botulinum toksin, ilaç olarak kullanılan ilk bakteriyel toksindir. Uygulama sonrası ilk belirtiler 2-5 günde ortaya çıkar ve 3-6 aylık bir süre zarfında kaslarda hiperaktivasyonun inhibisyonuna ve analjeziye neden olur. Botulinum toksinin baş boyun bölgesinde başlıca kullanım endikasyonları kronik ağrı, idiopatik trigeminal nevraljiler, TME rahatsızlıkları, , kronik baş ağrıları ve migrendir. Bu makalede botulinum toksin hakkında genel bir bilgi verilmiş, maksillofasiyal cerrahide kullanım alanları etki mekanizması ve kullanım dozları anlatılmıştır. Makaleler Science Direct, Pubmed, Medline taraması ile seçilmiştir

Anahtar Kelimeler

Botullinum toksin tip A, Botulinum toksin endikasyonları

Kaynakça

• Kinnett D.: Botulinum toxin A injections in children: tech- nique and dosing issues. Am J Phys Med Rehabil. 2004 Oct;83 (10 Suppl):S59-64.
• Umstadt HE.: Botulinum toxin in oromaxillofacial sur- gery. Mund Kiefer Gesichtschir. 2002 Jul;6 (4):249-60.
• Pidcock FS., Wise JM., Christensen JR.: Treatment of se- vere post traumatic bruxism with botulinum toxin-A: case report. J Oral Maxillofac Surg 2002; 60: 115-117
• Freund B., Schwartz M.: Clinical application of botuli- num toxin in the head and neck: AAOMS, 101. 200
• Dressler D, Saberi FA, Barbosa ER.: Botulinum toxin: me- chanisms of action. Arq Neuropsiquiatr. 2005 Mar;63 (1):180-5. Epub 2005 Apr 13.
• Purkiss J, Welch M, Doward S, Foster K.: Capsaicin-sti- mulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mecha- nisms. Biochem Pharmacol. 2000 Jun 1;59 (11):1403- 6.
• Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000 Mar-Apr;44 (2):106-9.
• Nixdorf DR, Heo G, Major PW.: Randomized controlled trial of botulinum toxin A for chronic myogenous orofa- cial pain. Pain. 2002 Oct;99 (3):465-73.
• Borodic G.E., Acquadro M.A.: The use of botulinum toxin for the treatment of chronic fascial pain, The Jour- nal of Pain, Vol:3, No:1 (feb) 2002:21-27
• Lang AM.: Botulinum toxin therapy for myofacial pain disorders. Current Pain and Headache Reports 2002; 6: 355-360
• Kamanli A., Kaya A., Ardicoglu O., Ozgocmen S., Zen- gin F.O.: Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2004 Sep 15
• Porta M.: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain form chronic muscle spasm. Pain. 2000 Mar; 85 (1-2):101-5
• Royal M.A.: The use of botulinum toxins in the mana- gement of pain and headache. Pain Pract. 2001 Sep; 1 (3):215-35
• Schwartz M: Poster 168 Dexamethasone and botulinum toxin type A in the teratment of chronic scar pain: A crossover study. Arch Phys Med Rehabil. 2004 S; 85 (9):E38
• Ravishankar K.: Botulinum toxin-role in headache prop- hylaxis, JAPI, Vol:51,September 2003:851-852
• Volcy-Gomez M.: The effectiveness and safety of botu- linum toxin in the treatment of chronic primary headac- hes, Rev Neurol 2004; 39 (4): 388-393
• Padberg M., de Brujin SF., de Haan RJ.,Tavy DL.: Tre- atment of chronic tension-type headache with botulinum toxin: a double blind, placebo-controlled trial. Cephalal- gia. 2004 Aug;24 (8):675-80
• Smuts JA., Schultz D., Barnard A.: Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004 sep;44 (8):801-5
• Gruener G., Jay W.: Treatment of headache with botulinum toxin administration. Semin opthalmol 2003;18:200-4
• Evers S., Vollmer-Haase J., Schwaag S., Rahman A., Husste FA.: Botulinum toxin A in the prophlactic treat- ment of migraine: a randomized, double-blind, plecebo controlled study. Cephalalgia 2004; 24:838-43
• Watts MW, Tan EK, Jankovic J.: Bruxism and cranial- cervical dystonia: is there a relationship? Cranio. 1999 Jul;17 (3):196-201.
• Schwartz M, Freund B.: Treatment of temporomandi- bular disorders with botulinum toxin. Clin J Pain. 2002 Nov-Dec;18 (6 Suppl):S198-203.
• Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G.: Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008 Apr;26 (2):126-35.
• von Lindern JJ, Niederhagen B, Bergé S, Appel T.: Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxil- lofac Surg. 2003 Jul;61 (7):774-8.
• Freund B, Schwartz M, Symington JM.: Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000 Oct;38 (5):466-71.
• Ahn KY, Kim ST.: The change of maximum bite force after botulinum toxin type a injection for treating mas- seteric hypertrophy. Plast Reconstr Surg. 2007 Nov;120 (6):1662-6.
• Aquilina P, Vickers R, McKellar G.: Reduction of a ch- ronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral Maxillofac Surg. 2004 Jun;42 (3):272-3.
• Ricardo G. Senno M.D.: Botulinum toxin type A in the treatment of temporomandibular joint dislocation in an adult with anoxic brain injury: a case report. Arch Phys Med Rehabil.2003 Sep;Vol:84
• Türk U, Ilhan S, Alp R, Sur H.: Botulinum toxin and in- tractable trigeminal neuralgia. Clin Neuropharmacol. 2005 Jul-Aug;28 (4):161-2.
• Zşñiga C, Díaz S, Piedimonte F, Micheli F.: Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr. 2008 Sep;66 (3A):500-3.